Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Medtech 2014 in Review

EP Vantage MedTech 2014 in Review

Download EP Vantage Medtech 2014 in Review

The one word to sum up the medtech sector in 2014 - megamergers. The total value of mergers reached nearly $40 billion, more than twice as much as 2013. Even more astonishing is the fact that this figure does not include the Medtronic-Covidien megamerger, which closed in early 2015.  

The number of companies going public also increased in 2014 with as many as 34 device makers conducting IPOs on Western exchanges.

Key highlights include:

  • FDA approved devices rose to 33 in 2014, a 43% increase from 2013
  • Seven of the top 10 M&A deals were worth more than $1bn, showing huge appetite for consolidation at the top
  • 34 device makers raised $2.2 billion in IPOs, more than triple the 2013 total
  • European markets were comparatively weak for both stock prices and IPOs
  • The total amount of venture funding in 2014 saw little change at $3.9 billion but the number of rounds dropped 15% from 406 in 2013 to 345 in 2014

Download EP Vantage Medtech 2014 in Review

Press Release

Related Reports: 

EP Vantage Pharma & Biotech 2014 in Review 

EvaluatePharma Japan Sales Volume Pricing 2015

EP Vantage CAR-T Therapy Landscape in 2015

EP Vantage Pharma & Biotech 2015 Preview